Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease

Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease

<p>Abstract</p> <p>Background</p> <p>The renin-angiotensin-aldosterone system (RAAS) plays an important role in the progression of chronic kidney disease (CKD). Although dual RAAS inhibition results in worse renal outcomes than monotherapy in high risk type 2 diabetes p...

Full description

Bibliographic Details
Main Authors:	Li Szu-yuan, Chen Yung-Tai, Yang Wu-Chang, Tarng Der-Cherng, Lin Chih-Ching, Yang Chih-Yu, Liu Wen-Sheng
Format:	Article
Language:	English
Published:	BMC 2012-08-01
Series:	BMC Nephrology
Subjects:	Aliskiren Direct renin inhibitor Proteinuria CKD
Online Access:	http://www.biomedcentral.com/1471-2369/13/89

Similar Items

ALISKIREN (RENIN INHIBITOR) AS THE RECENT ANTIHYPERTENSIVE MODALITY
by: Luh Gde Primahatini Suaka Putri
Published: (2013-12-01)

Aliskiren, Obat Antihipertensi Baru dengan Mekanisme Penghambat Renin
by: Diana Holidah
Published: (2011-12-01)

Aliskiren: An orally active renin inhibitor
by: Pranay Wal, et al.
Published: (2011-01-01)

Antidepressant-like Effects of Renin Inhibitor Aliskiren in an Inflammatory Mouse Model of Depression
by: Sami I. Alzarea, et al.
Published: (2022-05-01)

Renin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension
by: Karl Andersen
Published: (2009-03-01)

Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy
by: Kalathil K Sureshkumar
Published: (2008-12-01)

Direct renin inhibitor aliskiren in surgical treatment of nephrolithiasis
by: A.N., et al.
Published: (2013-03-01)

Direct renin inhibitor aliskiren in women with menopausal metabolic syndrome and arterial hypertension
by: Yu. V. Zhernakova, et al.
Published: (2011-08-01)

The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction
by: Paolo Verdecchia, et al.
Published: (2008-10-01)

The results of the open observational, international, multicenter, prospective program to assess the efficacy, safety and tolerability of the first direct renin inhibitor RasilezR (aliskiren) in patients with arterial hypertension in ‘real-life’ clinical practice settings (DRIve)
by: I Ye Chazova
Published: (2014-09-01)

Investigation renin inhibitor activity from flavonoids derivates by in silico study
by: Aprilita Rina Yanti Eff, et al.
Published: (2023-01-01)

A computer-generated plan to develop an intelligent biosensor for investigation of the inhibition of renin by aliskiren: A journey from inhibition to biosensing
by: Ali R. Jalalvand, et al.
Published: (2024-08-01)

Add-on aliskiren treatment can decrease blood pressure but requires attention to risks of renal impairment and hyperkalemia Chikushi Anti-Hypertension Trial-Rasilez® (CHAT-Ras)
by: Keisuke Okamura, et al.
Published: (2020-08-01)

Anti-fibrotic effect of Aliskiren in rats with deoxycorticosterone induced myocardial fibrosis and its potential mechanism
by: Likun Ma, et al.
Published: (2012-05-01)

Aliskiren administration during early postnatal life sex-specifically alleviates hypertension programmed by maternal high fructose consumption
by: You-Lin Tain, et al.
Published: (2016-07-01)

Renin as a target of direct pharmacological block in arterial hypertension
by: Nikolay Alekseevich Mukhin, et al.
Published: (2009-08-01)

Aliskiren and valsartan in combination is a promising therapy for hypertensive renal injury in rats
by: Hala Salah Abdel Kawy
Published: (2018-08-01)

COVID-19 and RAAS blockers: Could Aliskiren be an appropriate option?
by: Selçuk Şen, et al.
Published: (2020-10-01)

Protective Effects of Nanoparticle-Loaded Aliskiren on Cardiovascular System in Spontaneously Hypertensive Rats
by: Olga Pechanova, et al.
Published: (2019-07-01)

Clinical and economic impact of aliskiren in uncontrolled hypertensive patients
by: Ezio Degli Esposti, et al.
Published: (2012-03-01)

Therapeutic Implications of Renin–Angiotensin System Modulators in Alzheimer’s Dementia
by: Daniela-Carmen Ababei, et al.
Published: (2023-09-01)

The renin-angiotensin system and its blockers
by: Igić Rajko, et al.
Published: (2014-01-01)

Renoprotective effect of aliskiren monotherapy and aliskiren−pentoxifylline combination in hypertensive-diabetic type 2 patients with diabetic nephropathy
by: Amin T. Hamed, et al.
Published: (2013-12-01)

Aliskiren, a Direct Renin Inhibitor, Improves Vascular Endothelial Function in Patients on Hemodialysis Independent of Antihypertensive Effect ∼ a Pilot Study∼
by: Hidekazu Moriya, et al.
Published: (2013-05-01)

Budget impact analysis of use of aliskiren in hypertension on the Italian Health Care System
by: Orietta Zaniolo, et al.
Published: (2009-03-01)

Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews
by: Qiyuan Zhao, et al.
Published: (2020-04-01)

Effects of Aliskiren, an RAAS inhibitor, on a carrageenan-induced pleurisy model of rats
by: YASIN BAYIR, et al.
Published: (2018-12-01)

Royal Jelly and Aliskiren mutually annul their protective effects against gentamicin-induced nephrotoxicity in rats
by: Mohd Alaraj
Published: (2020-12-01)

Effects of Renin-Angiotensin System Inhibitors on Renal Expression of Renalase in Sprague-Dawley Rats Fed With High Salt Diet
by: Yang Wang, et al.
Published: (2015-11-01)

The Anti-Inflammatory Effect of Different Doses of Aliskiren in Rat Models of Inflammation
by: Aziz TA, et al.
Published: (2020-07-01)

COMBINATION OF DIRECT RENNIN INHIBITOR - ALISKIREN, ANGIOTENSIN II RECEPTOR BLOCKER - VALSARTAN, AND CALCIUM CHANNEL BLOCKER - AMLODIPINE, IN THERAPY OF HYPERTENSIVE PATIENT WITH GOUT (CASE REPORT)
by: O. V. Dralova, et al.
Published: (2016-01-01)

The Potential Effects of Aliskiren on Atrial Remodeling Induced by Chronic Intermittent Hypoxia in Rats
by: Miao S, et al.
Published: (2020-09-01)

Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors?
by: Elena Raccuglia, et al.
Published: (2009-11-01)

Aliskiren attenuates cardiac dysfunction by modulation of the mTOR and apoptosis pathways
by: Zhengbo Zhao, et al.
Published: (2020-01-01)

Comparative evaluation of aliskiren, ramipril, and losartan on psychomotor performance in healthy volunteers: A preliminary report
by: Ekta Arora, et al.
Published: (2014-01-01)

Effect of aliskiren, telmisartan and torsemide on cardiac dysfunction in l-nitro arginine methyl ester (l-NAME) induced hypertension in rats
by: Sawsan A. Sadek, et al.
Published: (2015-11-01)

Aliskiren Hemifumarate Proliposomes for Improved Oral Drug Delivery: Formulation Development, In Vitro and In Vivo Permeability Testing
by: Priyanka Kunamaneni, et al.
Published: (2022-07-01)

Investigating the beneficial effect of aliskiren in attenuating neuropathic pain in diabetic Sprague‐Dawley rats
by: Shouq Alkhudhayri, et al.
Published: (2021-04-01)

How to potentialize the effect of renin-angiotensin-aldosterone system inhibitors?
by: D.D. Ivanov
Published: (2021-09-01)

Therapeutic potential of Ganoderma lucidum polysaccharide peptide in Doxorubicin-induced nephropathy: modulation of renin-angiotensin system and proteinuria
by: Hui Fang, et al.
Published: (2023-09-01)